NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

WithdrawnPhase 2

Sponsor: Loxo Oncology, Inc.

Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis

Interventions: Placebo, Pirtobrutinib

Countries: United States, Puerto Rico

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants must have been diagnosed with relapsing MS
* Participants must have one of the following

  1. at least 1 documented relapse within the previous year, or
  2. at least 2 documented relapse within the previous 2 years, or
  3. at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

Exclusion Criteria:

* Have had a diagnosis of primary progressive MS
* Have a history of another clinically significant neurological disease
* Had a relapse of MS within 30 days prior to randomization.

Locations (4)

Tampa, Florida, United States
Houston, Texas, United States
Seattle, Washington, United States
Guaynabo, Puerto Rico